Lung Allograft Rejection Gene Expression Observational (LARGO) Study

NCT ID: NCT00751309

Last Updated: 2008-12-18

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

TERMINATED

Total Enrollment

2044 participants

Study Classification

OBSERVATIONAL

Study Start Date

2004-04-30

Study Completion Date

2009-01-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The objective of the LARGO Study protocol is to collect peripheral blood samples, select associated lung biopsy pathology slides, and clinical data from lung transplant recipients to perform molecular analyses in association with the study endpoints. The primary objective is to use gene expression profiling of peripheral blood mononuclear cells to differentiate between the absence and presence of acute cellular rejection. The secondary objectives are to use other genomic and proteomic technologies to analyze RNA and protein in blood samples in relation to related clinical conditions. The overall goal is to apply novel molecular insights in the development of non-invasive molecular diagnostic tests for lung transplantation.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

LARGO is a prospective, multi-center, international observational study with participating centers in the United States, Canada and Europe. The target enrollment for study completion is 2,100 subjects.

At each study visit, blood specimens are collected from subjects, processed and stored in the sample archive, with corresponding patient information entered into the clinical database. The analysis plan for each study objective includes a defined sample selection protocol that stipulates the inclusion and exclusion criteria for both patients and samples, and also the required number of blood specimens for the molecular analyses to achieve statistical significance.

The diagnosis and treatment of acute cellular rejection remains a clinical management priority that is currently based on transbronchial biopsy. Gene expression profiling is a technology based on molecular biology that measures changes in the RNA levels of different genes expressed by circulating mononuclear cells in the peripheral blood. A key goal of the project is to use gene expression profiling to differentiate between the absence and presence of lung allograft acute cellular rejection, with the aim of using this novel information to develop a non-invasive diagnostic testing alternative.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Graft Rejection Lung Disease

Keywords

Explore important study keywords that can help with search, categorization, and topic discovery.

allograft rejection biopsy gene expression pulmonary lung transplant

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

COHORT

Study Time Perspective

PROSPECTIVE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

1

Lung and heart-lung transplanted subjects.

Non-interventional

Intervention Type OTHER

Post-transplantation observational study

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Non-interventional

Post-transplantation observational study

Intervention Type OTHER

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Lung and heart-lung transplant recipients who consent to participate and have transbronchial biopsy at the enrolling center during the study period

Exclusion Criteria

* None
Eligible Sex

ALL

Accepts Healthy Volunteers

Yes

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

XDx

INDUSTRY

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

XDx, Inc.

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Kenneth C. Fang, MD

Role: STUDY_DIRECTOR

XDx, Inc.

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

UCLA Division of Pulmonary and Critical Care

Los Angeles, California, United States

Site Status

University of California, San Francisco

San Francisco, California, United States

Site Status

Stanford University School of Medicine

Stanford, California, United States

Site Status

University of Colorado

Aurora, Colorado, United States

Site Status

Mayo Clinic Transplant Center

Jacksonville, Florida, United States

Site Status

University of Michigan Health Systems

Ann Arbor, Michigan, United States

Site Status

St. Louis Children's Hospital

St Louis, Missouri, United States

Site Status

Washington University School of Medicine

St Louis, Missouri, United States

Site Status

Columbia University College of Physicians and Surgeons

New York, New York, United States

Site Status

Duke University Medical Center

Durham, North Carolina, United States

Site Status

The Cleveland Clinic

Cleveland, Ohio, United States

Site Status

University of Pennsylvania

Philadelphia, Pennsylvania, United States

Site Status

University of Pittsburgh

Pittsburgh, Pennsylvania, United States

Site Status

University of Washington Medical Center

Seattle, Washington, United States

Site Status

University Hospital and Clinics

Madison, Wisconsin, United States

Site Status

Medizinische Universität Wien

Vienna, , Austria

Site Status

Hospital for Sick Children

Toronto, Ontario, Canada

Site Status

Toronto General Hospital

Toronto, Ontario, Canada

Site Status

Medizinische Hochschule Hannover

Hanover, , Germany

Site Status

Freeman Hospital

High Heaton, Newcastle upon Tyne, United Kingdom

Site Status

Countries

Review the countries where the study has at least one active or historical site.

United States Austria Canada Germany United Kingdom

Related Links

Access external resources that provide additional context or updates about the study.

http://www.xdx.com/allomap

Information on molecular expression testing

http://www.xdx.com

Sponsor's website

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

LARGO

Identifier Type: -

Identifier Source: org_study_id